Barclays analyst Carter Gould maintained a Hold rating on Gossamer Bio (GOSS – Research Report) today and set a price target of $0.50. The company’s shares closed last Friday at $1.38.
According to TipRanks, Gould is a 5-star analyst with an average return of 11.2% and a 58.11% success rate. Gould covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Regeneron.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gossamer Bio with a $7.25 average price target.
See the top stocks recommended by analysts >>
Based on Gossamer Bio’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $48.15 million. In comparison, last year the company had a GAAP net loss of $55.76 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gossamer Bio (GOSS) Company Description:
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate is GB001, which is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Read More on GOSS:
